Announcements

Removal of Component(s) – RYZB

February 20, 2024

LifeSci Biotechnology Clinical Trials Index

Effective at the market close on Thursday, February 22, 2024, RYZB will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights.

On December 26, 2023, RayzeBio, Inc. announced that it would be acquired by Bristol Myers for $62.50/share in cash.